Suitable signal peptides for secretory production of recombinant granulocyte colony stimulating factor in Escherichia coli

被引:13
作者
Tehrani S.S. [1 ,2 ]
Goodarzi G. [1 ,2 ,3 ]
Naghizadeh M. [1 ,2 ]
Khatami S.H. [4 ]
Movahedpour A. [5 ,6 ]
Abbasi A. [4 ]
Shabaninejad Z. [7 ,8 ]
Khalaf N. [8 ]
Taheri-Anganeh M. [9 ]
Savardashtaki A. [5 ,10 ]
机构
[1] Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran
[2] Student Scientific Research Center, Tehran University of Medical Sciences, Tehran
[3] Department of Clinical Biochemistry, School of Medicine, North Khorasan University of Medial Sciences, Bojnourd
[4] Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz
[5] Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz
[6] Student Research Committee, Shiraz University of Medical Scienc-es, Shiraz
[7] Department of Nanobiotechnology, School of Basic Sciences, Tarbiat Modares University, Tehran
[8] Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz
[9] Cellular and Molecular Research Center, Research Institute on Cellular and Molecular Medicine, Urmia University of Medical Sciences, Urmia
[10] Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz
关键词
Bioinformatics; Biopharmaceutical; Filgrastim; G-CSF; Recombinant protein; Signal peptide;
D O I
10.2174/1872208314999200730115018
中图分类号
学科分类号
摘要
Background: Granulocyte colony-stimulating factor (G-CSF) expressed in engi-neered Escherichia coli (E. coli) as a recombinant protein is utilized as an adjunct to chemotherapy for improving neutropenia. Recombinant proteins overexpression may lead to the crea-tion of inclusion bodies whose recovery is a tedious and costly process. To overcome the problem of inclusion bodies, secretory production might be used. To achieve a mature secretory protein product, suitable signal peptide (SP) selection is a vital step. Objective: In the present study, we aimed at in silico evaluation of proper SPs for secretory production of recombinant G-CSF in E. coli. Methods: Signal peptide website and UniProt were used to collect the SPs and G-CSF sequenc-es. Then, SignalP were utilized in order to predict the SPs and location of their cleavage site. Physicochemical features and solubility were investigated by ProtParam and Protein-sol tools. Fusion proteins sub-cellular localization was predicted by ProtCompB. Results: LPP, ELBP, TSH, HST3, ELBH, AIDA and PET were excluded according to SignalP. The highest aliphatic index belonged to OMPC, TORT and THIB and PPA. Also, the highest GRAVY belonged to OMPC, ELAP, TORT, BLAT, THIB, and PSPE. Furthermore, G-CSF fused with all SPs were predicted as soluble fusion proteins except three SPs. Finally, we found OMPT, OMPF, PHOE, LAMB, SAT, and OMPP can translocate G-CSF into extracellular space. Conclusion: Six SPs were suitable for translocating G-CSF into the extracellular media. Alt-hough growing data indicate that the bioinformatics approaches can improve the precision and ac-curacy of studies, further experimental investigations and recent patents explaining several in-ventions associated to the clinical aspects of SPs for secretory production of recombinant G-CSF in E. coli are required for final validation. © 2020 Bentham Science Publishers.
引用
收藏
页码:269 / 282
页数:13
相关论文
共 54 条
[1]  
Rader RA., Redefining biopharmaceutical, Nat Biotechnol, 26, 7, pp. 743-751, (2008)
[2]  
Mehta HM, Malandra M, Corey SJ., G-CSF and GM-CSF in Neutropenia, J Immunol, 195, 4, pp. 1341-1349, (2015)
[3]  
Wittman B, Horan J, Lyman GH., Prophylactic colo-ny-stimulating factors in children receiving myelo-suppressive chemotherapy: a meta-analysis of randomized controlled trials, Cancer Treat Rev, 32, 4, pp. 289-303, (2006)
[4]  
Yang B-B, Kido A., Pharmacokinetics and pharmaco-dynamics of pegfilgrastim, Clin Pharmacokinet, 50, 5, pp. 295-306, (2011)
[5]  
Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G., Filgrastim (r-metHuG-CSF): the first 10 years, (1996)
[6]  
Sivakumaran M, Vasconcelos ZF, Diamond HR, Tabak DG, Barcinski MA, Bonomo A, Et al., Fil-grastim prevents severe neutropenia and reduces in-fective morbidity in patients with advanced HIV in-fection: results of a randomized, multicenter, controlled trial. G-CSF 930101 study group, Blood, 97, 1, pp. 333-335, (2001)
[7]  
Babalola CP, Nightingale CH, Nicolau DP., Adjunc-tive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts, J Antimi-crob Chemother, 53, 6, pp. 1098-1100, (2004)
[8]  
Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME., Randomised pla-cebo-controlled trial of granulocyte-colony stimulat-ing factor in diabetic foot infection, Lancet, 350, 9081, pp. 855-859, (1997)
[9]  
Vanz AL, Renard G, Palma MS, Chies JM, Dalmora SL, Basso LA, Et al., Human granulocyte colony stimulating factor (hG-CSF): cloning, overexpression, purification and characterization, Microb Cell Fact, 7, 1, (2008)
[10]  
Kesik-Brodacka M., Progress in biopharmaceutical development, Biotechnol Appl Biochem, 65, 3, pp. 306-322, (2018)